AbbVie presents cancer drug data at EHA annual congress

AbbVie is sharing its latest haematologic oncology research findings at the annual congress of the European Hematology Association (EHA) in Copenhagen this week.

A total of ten abstracts are being presented by the company on its investigational medicine venetoclax, a B-cell lymphoma-2 inhibitor, as well as a presentation on duvelisib, its investigational phosphoinositide-3-kinase-delta and PI3K-gamma inhibitor. 

The findings demonstrate the effectiveness of these therapies against some of the most common haematological malignancies, including chronic lymphocytic leukaemia, multiple myeloma, acute myeloid leukaemia and follicular lymphoma.

AbbVie's research into these therapies shows how it is leveraging its expertise in this field to explore novel mechanisms of action and administration to disrupt cancer development and growth in blood cancers.

Dr Michael Severino, executive vice-president of research and development and chief scientific officer at AbbVie, said: "The data underscore AbbVie's growing haematology portfolio and our commitment to changing the way blood cancer is treated with innovative new treatment options."

This comes after the firm recently attended the annual meeting of the American Society of Clinical Oncology, where it presented new clinical data demonstrating the safety and efficacy of its drug Imbruvica.